Get the Stockscreener App
44.93
5.12%
2.19
After Hours:
45.50
0.57
+1.27%
Harrow Inc stock is traded at $44.93, with a volume of 945.80K.
It is up +5.12% in the last 24 hours and up +35.37% over the past month.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
See More
Previous Close:
$42.74
Open:
$43.15
24h Volume:
945.80K
Relative Volume:
1.21
Market Cap:
$1.67B
Revenue:
$272.30M
Net Income/Loss:
$-5.14M
P/E Ratio:
-274.80
EPS:
-0.1635
Net Cash Flow:
$42.76M
1W Performance:
+9.19%
1M Performance:
+35.37%
6M Performance:
-16.02%
1Y Performance:
+41.51%
1-Day Range:
$42.59
$45.34
1-Week Range:
$41.40
$45.34
52-Week Range:
$28.54
$54.85
Harrow Inc Stock (HROW) Company Profile
Name
Harrow Inc
Sector
Phone
615.733.4731
Address
1A BURTON HILLS BLVD, NASHVILLE, CA
Compare HROW vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HROW
Harrow Inc
|
44.93 | 1.58B | 272.30M | -5.14M | 42.76M | -0.1635 |
TAK
Takeda Pharmaceutical Co Adr
|
16.89 | 50.65B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.72 | 41.09B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.29 | 39.45B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
75.42 | 30.13B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
547.25 | 23.00B | 3.17B | 1.29B | 1.01B | 27.09 |
Harrow Inc Stock (HROW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-11-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-12-25 | Initiated | BTIG Research | Buy |
| Jun-10-25 | Initiated | William Blair | Outperform |
| Feb-06-25 | Initiated | H.C. Wainwright | Buy |
| Dec-04-24 | Reiterated | B. Riley Securities | Buy |
| Apr-11-24 | Initiated | Craig Hallum | Buy |
| Sep-08-22 | Resumed | B. Riley Securities | Buy |
| Oct-14-21 | Resumed | B. Riley Securities | Buy |
| Sep-24-21 | Initiated | Aegis Capital | Buy |
| Jul-02-21 | Initiated | Ladenburg Thalmann | Buy |
View All
Harrow Inc Stock (HROW) Latest News
Enterprise value to EBITDA forward of Harrow, Inc. – NASDAQ:HROW - TradingView
Price to sales forward of Harrow, Inc. – NASDAQ:HROW - TradingView
Harrow Expands Retina Portfolio With US Launch of Byooviz - marketscreener.com
Harrow (HROW) Launches Byooviz, FDA-Approved Biosimilar - GuruFocus
Harrow (HROW) Launches BYOOVIZ Biosimilar in U.S. Market - GuruFocus
A first FDA-approved eye biosimilar returns to U.S. sales - Stock Titan
Harrow Announces Commercial Launch of BYOOVIZ® in the United States - GlobeNewswire
A Look at Harrow Inc (HROW) After 3.2% Gain -- GF Value $42.31 v - GuruFocus
Harrow, Inc. Actuals & Estimates (NASDAQ:HROW) - TradingView
HROW Forecast — Price Target — Prediction for 2027 - TradingView
How Grow Funds’ Exit and Weaker Earnings Recast Harrow’s (HROW) Growth Narrative and Governance Choices - simplywall.st
Harrow Inc (HROW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
GROW Small Cap Equity Fund Covered Its Position in Harrow (HROW) in Q1 - Insider Monkey
Form 4 Harrow Health Inc For: 22 June By Investing.com - Investing.com Australia
[Form 4] HARROW, INC. Insider Trading Activity - Stock Titan
Harrow (HROW) director Adrienne Graves receives 5,248 RSUs as compensation grant - Stock Titan
Harrow (HROW) director granted 5,248 restricted stock units as compensation - Stock Titan
Form 8K Harrow Health Inc For: 22 June By Investing.com - Investing.com Australia
Harrow elects directors and approves executive compensation at annual meeting - Investing.com
Harrow, Inc. (NASDAQ: HROW) 2026 Annual Meeting Results: Shareholder Votes and Key Decisions from Form 8-K Filing – Minichart - Minichart
Harrow (HROW) investors back all 2026 director, pay and auditor proposals - Stock Titan
Harrow Inc (HROW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
HROW News | HARROW INC (NASDAQ:HROW) - ChartMill
$Harrow (HROW.US)$ i shouldve put more in - Moomoo
Spotlight On Harrow And 2 Other Growth Stocks With Strong Insider Backing - simplywall.st
Harrow Inc (HROW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Harrow Inc (HROW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Harrow Inc (HROW) Institutional Confidence - TradingKey
Harrow Inc (HROW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Harrow Inc (HROW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Harrow Inc (HROW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Harrow Inc (HROW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Is Harrow, Inc. (HROW) A Good Stock To Buy Now? - Insider Monkey
Can Harrow’s (HROW) VERKAZIA Relaunch Redefine Its Niche Ophthalmic Strategy? - Yahoo Finance
Harrow Adds Another Piece To Ophthalmology Strategy - Benzinga
HROW Stock Rises on Relaunch of Ophthalmology Drug Verkazia in the US - TradingView
What Harrow (HROW)'s VERKAZIA Re‑Launch in Pediatric VKC Means For Shareholders - Sahm
HROW Stock Rips Higher As Traders Digest Mixed Quarter - timothysykes.com
Analysts Are Bullish on Top Healthcare Stocks: Harrow Health (HROW), GeneDx Holdings (WGS) - The Globe and Mail
Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic - GlobeNewswire
Return on invested capital % of Harrow, Inc. – FWB:3IP - TradingView
Harrow Inc. Q1 2026 Earnings: Significant EPS Miss Triggers Stock DeclineBook Value Growth - newsline.com
HARROW INC (HROW) Stock Chart - ChartMill
What Does Cantor Fitzgerald Think About Harrow (HROW) After Cutting Its Price Target? - Insider Monkey
Harrow Health Inc stock (US4158581094): Ophthalmology player trades below analyst targets amid secto - AD HOC NEWS
Harrow Inc. (HROW) Q1 2026 Earnings: Significant Earnings Miss Despite Positive Stock ReactionPeak Earnings Alert - newsline.com
William Blair Maintains Harrow(HROW.US) With Buy Rating - Moomoo
Harrow Health Releases June 2026 Investor Presentation Update - TipRanks
Harrow files Regulation FD disclosure to furnish June 2026 corporate presentation - TradingView
Harrow Inc Stock (HROW) Financials Data
Revenue
Net Income
Cash Flow
EPS
Harrow Inc Stock (HROW) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SILVERNAIL LAUREN P | Director |
May 18 '26 |
Buy |
31.00 |
1,000 |
31,000 |
1,000 |
| BAUM MARK L | CHIEF EXECUTIVE OFFICER |
May 14 '26 |
Buy |
30.20 |
10,000 |
302,000 |
2,996,130 |
| BOLL ANDREW R. | PRESIDENT AND CFO |
May 14 '26 |
Buy |
29.90 |
3,500 |
104,650 |
814,679 |
| Opaleye Management Inc. | 10% Owner |
Mar 04 '26 |
Sale |
39.67 |
138,263 |
5,485,184 |
59,428 |
| Opaleye Management Inc. | 10% Owner |
Mar 03 '26 |
Sale |
39.15 |
60,309 |
2,361,242 |
63,691 |
| Opaleye Management Inc. | 10% Owner |
Feb 27 '26 |
Sale |
54.18 |
5,000 |
270,900 |
65,000 |
| Opaleye Management Inc. | 10% Owner |
Jan 06 '26 |
Sale |
53.35 |
20,000 |
1,066,914 |
70,000 |
| BOLL ANDREW R. | PRESIDENT AND CFO |
Dec 12 '25 |
Option Exercise |
3.95 |
60,000 |
237,000 |
837,844 |
| BAUM MARK L | CHIEF EXECUTIVE OFFICER |
Dec 12 '25 |
Option Exercise |
3.95 |
180,000 |
711,000 |
3,066,124 |
| BAUM MARK L | CHIEF EXECUTIVE OFFICER |
Jul 21 '25 |
Option Exercise |
7.87 |
600,000 |
4,722,000 |
3,199,462 |
1.03%
0.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):